Dr. Ritesh Parajuli, MD
Claim this profileUC Irvine Health/Chao Family Comprehensive Cancer Center
Expert in Breast Cancer
Studies Cancer
18 reported clinical trials
44 drugs studied
Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
2Cancer
Stage IV
HER2 positive
ER positive
Affiliated Hospitals
Clinical Trials Ritesh Parajuli, MD is currently running
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
TBio-4101 + Pembrolizumab
for Advanced Solid Cancers
A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.
Recruiting1 award Phase 15 criteria
More about Ritesh Parajuli, MD
Clinical Trial Related6 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Ritesh Parajuli, MD has experience with
- Pembrolizumab
- Paclitaxel
- Trastuzumab
- Pertuzumab
- Abemaciclib
- Durvalumab
Breakdown of trials Ritesh Parajuli, MD has run
Breast Cancer
Cancer
Tumors
Endometrial Cancer
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ritesh Parajuli, MD specialize in?
Ritesh Parajuli, MD focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 negative.
Is Ritesh Parajuli, MD currently recruiting for clinical trials?
Yes, Ritesh Parajuli, MD is currently recruiting for 9 clinical trials in Orange California. If you're interested in participating, you should apply.
Are there any treatments that Ritesh Parajuli, MD has studied deeply?
Yes, Ritesh Parajuli, MD has studied treatments such as Pembrolizumab, Paclitaxel, Trastuzumab.
What is the best way to schedule an appointment with Ritesh Parajuli, MD?
Apply for one of the trials that Ritesh Parajuli, MD is conducting.
What is the office address of Ritesh Parajuli, MD?
The office of Ritesh Parajuli, MD is located at: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California 92868 United States. This is the address for their practice at the UC Irvine Health/Chao Family Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.